Inappropriate Use Of Amfepramone Prompts EU Withdrawal Of Weight-Loss Drug
EMA Issues Warning Over Xalkori And Oular Toxicity In Pediatric Patients
Executive Summary
The European Medicines Agency’s pharmacovigilance committee has recommended removing all amfepramone medicines from the EU market as they continue to be used outside the current risk minimization measures.
You may also be interested in...
The ECJ's Judgment in the Anorectics Case: Effects on Referrals and Variations
Markus Ambrosius examines the implications for pharmaceutical companies of the recent court ruling.
Anorectic Drugs
Court rejects European ban
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.